SCHEMBL2774071

SCHEMBL2774071

COc1ccccc1-c1ccc(-c2nc(-c3ccc(C(=O)O)c(F)c3)no2)cc1C

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 13/20 0.67
S1PR3 Q99500 1/20 0.65
NPC1 O15118 4/20 0.56
RAB9A P51151 4/20 0.56
SMN1; SMN2 Q16637 4/20 0.56
ALDH1A1 P00352 3/20 0.56
HSD17B10 Q99714 3/20 0.56
HPGD P15428 2/20 0.56
KDM4E B2RXH2 1/20 0.56
TSHR P16473 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
RARA P10276 3/20 0.54
RARB P10826 3/20 0.54
RARG P13631 3/20 0.54
TP53 P04637 3/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
RXFP1 Q9HBX9 1/20 0.51
MEN1 O00255 1/20 0.49
NFKB1 P19838 1/20 0.49
NFKB2 Q00653 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2772255 0.92 S1PR1 (0.64) S1PR1S1PR3NPC1RAB9ASMN1; SMN2
SCHEMBL2809498 0.92 S1PR1 (0.70) S1PR1S1PR3NPC1RAB9ASMN1; SMN2
SCHEMBL2807738 0.90 S1PR1 (0.71) S1PR1S1PR3NPC1RAB9ARARA
SCHEMBL2803950 0.89 S1PR1 (0.56) S1PR1S1PR3NPC1RAB9ASMN1; SMN2
SCHEMBL2772526 0.89 S1PR1 (0.56) S1PR1S1PR3NPC1RAB9ASMN1; SMN2
SCHEMBL2807888 0.88 S1PR1 (0.64) S1PR1S1PR3NPC1RAB9ARARA
SCHEMBL2772454 0.87 S1PR1 (0.62) S1PR1S1PR3NPC1RAB9ARARA
SCHEMBL2772342 0.87 S1PR1 (0.76) S1PR1S1PR3NPC1RAB9ASMN1; SMN2
SCHEMBL2772693 0.87 S1PR1 (0.61) S1PR1S1PR3NPC1RAB9ARARA
SCHEMBL2771892 0.86 S1PR1 (0.69) S1PR1S1PR3NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2193125-B1 OXADIAZOLE DERIVATIVES MERCK SERONO SA (CH) 2017-01-11 EP disclosed
EP-2193125-B1 OXADIAZOLE DERIVATIVES MERCK SERONO SA (CH) 2017-01-11 EP disclosed
US-8202865-B2 Oxadiazole derivatives MERCK SERONO SA (CH) 2012-06-19 US disclosed
US-8202865-B2 Oxadiazole derivatives MERCK SERONO SA (CH) 2012-06-19 US disclosed
US-8202865-B2 Oxadiazole derivatives MERCK SERONO SA (CH) 2012-06-19 US disclosed
US-20100240658-A1 Oxadiazole Derivatives MERCK SERONO SA (CH) 2010-09-23 US disclosed
US-20100240658-A1 Oxadiazole Derivatives MERCK SERONO SA (CH) 2010-09-23 US disclosed
US-20100240658-A1 Oxadiazole Derivatives MERCK SERONO SA (CH) 2010-09-23 US disclosed
EP-2193125-A2 OXADIAZOLE DERIVATIVES Merck Serono S.A. (CH) 2010-06-09 EP disclosed
WO-2009043889-A2 OXADIAZOLE DERIVATIVES MERCK SERONO S.A. (CH) 2009-04-09 WO disclosed
WO-2009043889-A2 OXADIAZOLE DERIVATIVES MERCK SERONO S.A. (CH) 2009-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240658-A1 Oxadiazole Derivatives OXA1L, RO60, NQO2 S1PR1 483/4885S1PR3 335/4885NPC1 4814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.